BioSpace News Archive

CG Oncology presented positive interim Phase II results for its Core1 trial studying the use of CG0070 at the American Association for Cancer Research (AACR) Annual Meeting.

BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.

The SEC added 12 China companies to their delisting watchlist this week. The companies will need to release evidence by May 3 to remain listed.

The biobanking market has been estimated to experience novel growth opportunities in the forthcoming years.

Albany NY, United States: Human chorionic gonadotropin hormone, luteinizing hormone, and follicle stimulating hormone are some of the reproductive hormones which are quantitatively detected using the tools of fertility along with pregnancy rapid test kits.

Albany NY, United States: Atherosclerotic plaques form into coronary arteries and vein grafts causing coronary heart diseases.

The hemodynamic monitoring market has been expected to grow at a noteworthy speed in the coming years.

BeiGene, Ltd. announced that the China National Medical Products Administration has granted approval to BeiGene’s anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma who have disease progression or are intolerant to first-line standard chemotherapy.

HRH is Only Hospital in Hudson County with Any SRC Accreditation.

Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET.